AA
CERE

ALPS Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

ALPS Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-128,068
Closed -$5.41M – 1010
2024
Q1 		$5.41M Buy
128,068
+30,379
+31% +$1.28M 0.04% 230
2023
Q4 		$4.14M Sell
97,689
-18,574
-16% -$534K 0.03% 238
2023
Q3 		$2.54M Buy
116,263
+984
+0.9% +$24.6K 0.02% 288
2023
Q2 		$3.66M Buy
115,279
+12,069
+12% +$370K 0.03% 220
2023
Q1 		$2.52M Sell
103,210
-2,856
-3% -$83.8K 0.02% 249
2022
Q4 		$3.35M Buy
106,066
+21,096
+25% +$595K 0.03% 220
2022
Q3 		$2.4M Sell
84,970
-2,999
-3% -$89.3K 0.02% 276
2022
Q2 		$2.33M Sell
87,969
-64,146
-42% -$1.82M 0.02% 290
2022
Q1 		$5.33M Sell
152,115
-18,284
-11% -$534K 0.06% 128
2021
Q4 		$5.52M Sell
170,399
-7,166
-4% -$253K 0.06% 143
2021
Q3 		$5.24M Buy
177,565
+10,582
+6% +$297K 0.05% 171
2021
Q2 		$4.28M Buy
+166,983
New +$2.39M 0.04% 184

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ALPS Advisors's CERE Position: Q2 2024 in Review

ALPS Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2024, closing a stake of 128,068 shares — an estimated $5.41M sold.

ALPS Advisors first reported a position in CERE in Q2 2021 and held it in 12 quarters. The position peaked at $5.52M in Q4 2021. 231 funds tracked by Wall St. Rank hold CERE as of Q2 2024.

  • ALPS Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • ALPS Advisors sold 128,068 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2024, an estimated $5.41M.
  • ALPS Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2021 and held it in 12 quarters.
  • ALPS Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $5.52M in Q4 2021.
  • 231 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2024.

Based on ALPS Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.